(Rule of thumb in older patients with leukemia)
1-year survival: 15%-20%

Zarnestra® 2005 ODAC cited
-1-yr. survival: 15%

Cytarabine & anthracycline (7+3 regimen)
1-yr survival 10% - 18%

Sapacitabine
1-yr survival 30%

Not only that, Sapacitabine’s has demonstrated the best results across the board including: response rate, durability of response, side effects and rate of death within 30 days from all causes.

In case some folks are not familiar with survival rates and elderly AML...

;-)